• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

A study on pharmacoeconomics analysis of antihypertensive drugs

    Dr. Syed Sujat Pasha,Dr.Sha NaseeruddinMakandar, Dr.Lakshmipathi BS

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 951-957

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Hypertension is one of the leading cause of global burden of diseases and as it is a chronic
condition with significant detrimental effects on the wide range of health outcomes, cost
effective management of hypertension appears to be a great challenge for both developed as
well as developing countries. Even though recently there have been lot of studies on
pharmacoeconomics and outcome research in the field of hypertension globally, but the
results cannot be exactly extrapolated to Indian scenario as the economic status and
socioeconomic factors are different in India as compared to the countries. Hence a study was
undertaken to evaluate the cost effective antihypertensive drugs in our hospital. An
observational comparative study is planned on 100 patients attending the outpatient
Department of General medicine with a follow up period of 6 months. Written informed
consent is obtained from all the patients satisfying the inclusion criteria. Multitherapy was
frequently prescribed (74%), out of that Atenolol with Amlong combination was most
common (54%). Diabetes was the most common co-morbid condition (24%). Multitherapy
was most frequently prescribed, and Amlodipine with Enalapril combination proved to be
most cost effective therapy. HRQoL was not much different in all the treatment groups.
Keywords:
    Hypertension pharmacoeconomics quality of life (QoL) SF-36 questionnare Cost Effective Ratio (CER)
  • PDF (189 K)
  • XML
(2022). A study on pharmacoeconomics analysis of antihypertensive drugs. European Journal of Molecular & Clinical Medicine, 9(1), 951-957.
Dr. Syed Sujat Pasha,Dr.Sha NaseeruddinMakandar, Dr.Lakshmipathi BS. "A study on pharmacoeconomics analysis of antihypertensive drugs". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 951-957.
(2022). 'A study on pharmacoeconomics analysis of antihypertensive drugs', European Journal of Molecular & Clinical Medicine, 9(1), pp. 951-957.
A study on pharmacoeconomics analysis of antihypertensive drugs. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 951-957.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 40
  • PDF Download: 42
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus